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Abstract
QuantiFERON-Gold TB (QFT)-positive patients with undetermined cause of uveitis are
problematic in terms of whether to diagnose and treat them for tuberculosis (TB). Here, we
investigated whether peripheral blood expression of type 1 interferon (IFN)-inducible genes
may be of use to stratify QFT-positive patients with uveitis into groups of high versus low
risk of having active TB-associated uveitis. We recruited all new uveitis patients in Cipto
Mangunkusumo Hospital, Jakarta, Indonesia for one year. We included 12 patients with
uveitis and clinically diagnosed active pulmonary TB, 58 QFT-positive patients with uveitis
of unknown cause, 10 newly diagnosed sputum-positive active pulmonary TB patients with-
out uveitis and 23 QFT-negative healthy controls. Expression of 35 type 1 IFN-inducible
genes was measured in peripheral blood cells from active pulmonary TB patients without
uveitis and healthy controls. Differentially expressed genes were identified and used for fur-
ther clustering analyses of the uveitis groups. A type-1 IFN gene signature score was calcu-
lated and the optimal cut-off value for this score to differentiate active pulmonary TB from
healthy controls was determined and applied to QFT-positive patients with uveitis of
unknown cause. Ten type 1 IFN-inducible genes were differentially expressed between
active pulmonary TB and healthy controls. Expression of these 10 genes in QFT-positive
patients with uveitis of unknown cause revealed three groups: 1); patients resembling active
pulmonary TB, 2); patients resembling healthy controls, and 3); patients displaying an in-
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between gene expression pattern. A type 1 IFN gene signature score�5.61 displayed high
sensitivity (100%) and specificity (91%) for identification of active TB. Application of this
score to QFT-positive patients with uveitis of unknown cause yielded two groups with
expected different likelihood (high vs. low) of having active-TB uveitis, and therefore may be
useful in clinical management decisions.
Introduction
Tuberculosis (TB) is one of the major health problems worldwide. TB-associated uveitis repre-
sents a major cause of infectious uveitis in Indonesia and in other countries endemic for TB.
[1–5] The diagnosis of TB uveitis is mainly based on microbiological proof of active TB infec-
tion in the eye or a positive culture in other organs, most frequently the lungs. However, the
diagnosis TB uveitis is challenging in the absence of clinically apparent pulmonary disease
because ocular tissue examinations are not readily available and biopsies are troublesome to
perform.[6]
The advent of the IFN-γ release assay (IGRA) or QuantiFERON Gold TB (QFT) test
enabled the identification of individuals with a prior Mycobacterium tuberculosis (Mtb) infec-
tion. However, although the QFT test provides evidence of an immune response to Mtb, it
lacks the specificity to distinguish between active and latent TB.[7] Whether QFT-positive uve-
itis is the result of a direct infection of the retina, an anti-retinal immune response in QFT-pos-
itive individuals or a combination of both is unclear.[8] Therefore, using QFT as a diagnostic
test for active TB is not feasible in cases suspect of active TB uveitis.
Histopathological studies in patients with uveitis, but without pathological lung findings,
documented a Mtb infection of the retinal pigment epithelium (RPE). This finding shows that
ocular infection may be present even in patients without signs of active systemic TB.[9, 10]
Anti-tuberculous therapy (ATT) treatment can be very successful in a part of QFT-positive
uveitis of unknown cause, but the results in all QFT-positive patients are not conclusive.[11,
12] Thus, whether a patient has uveitis due to active TB infection, retinal autoimmunity or a
combination of both is unclear. Discrimination of active TB infection from latent TB infec-
tion-associated uveitis is an important goal for adjusting therapy and optimizing visual out-
comes in patients with QFT-positive uveitis.
Recent reports have indicated that active TB is associated with a specific activation pattern
of the type 1 IFN signaling cascade.[13–16] Active pulmonary TB can be discriminated from
latent TB by the expression of type 1 IFN-inducible genes in immune cells.[13, 15] In this
study, we explore whether the expression of type 1 IFN-inducible genes in peripheral blood
cells from patients with QFT-positive uveitis can serve as a tool to stratify these patients into
groups with a high or low likelihood of having active TB uveitis.
Patients and methods
Patients
Patients with uveitis were selected from a prospective uveitis cohort study (June 2014 to May
2015) in which we consecutively recruited 247 patients (after receiving informed consent) with
new uveitis referred to the Infection and Immunology Division of the Ophthalmology Depart-
ment of the Medical Faculty Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta,
Indonesia. The clinical part of the study has been recently published.[1] For the present study,
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we excluded 177 of these 247 uveitis patients for the following reasons: 72 had an incomplete
screening workup, 29 were human immunodeficiency virus (HIV) positive, 53 were Quanti-
FERON-Gold TB (QFT)-negative, 2 had an indeterminate QFT value without evidence of clin-
ically active TB, and 21 QFT-positive patients had another established cause of uveitis. In total,
we included 12 cases with uveitis with clinically diagnosed active pulmonary TB (of whom two
were Mtb sputum-positive and 10 were Mtb sputum-negative) and 58 patients with uveitis
who were QFT-positive without any signs of active TB and in whom no alternative cause for
uveitis could be established (Tables 1 and 2). All included patients had active uveitis and only
two patients were already receiving ATT at the time of blood sampling.
As a positive control group, we additionally included 10 Mtb sputum-positive active pulmo-
nary TB patients (HIV negative) without uveitis or a history of ATT from the outpatient clinic
of Persahabatan Hospital, East Jakarta, Indonesia. We also included 23 Indonesian healthy
controls who were QFT-negative, had no history of uveitis and did not use any medication at
the time of the study.
All included patients underwent a full ophthalmic examination. The uveitis classification
and grading were performed according to standardized uveitis nomenclature (SUN).[17] The
diagnosis and workup were performed as described previously.[1] QFT was performed for all
included uveitis patients with the QuantiFERON-Tb Gold (QFT; Cellestis Inc., Carnegie, Aus-
tralia) test using a positive cut-off value of>0.35 U/mL.[1] The tuberculin skin test (TST)
(RT23 SSI-2 T.U/0.1 mL, Statens Serum Institute, Copenhagen, Denmark) was performed in
59/70 uveitis patients due to a temporary unavailability of tuberculin. The TST was considered
positive in patients with an induration larger than 10 mm in diameter.[18] The QFT was
always performed before the TST, and the TST was not performed in the healthy controls or
the active pulmonary TB patients without uveitis.
Diagnosis of pulmonary TB
Pulmonary TB was diagnosed according to the Tuberculosis Guidelines from the Indonesian
Society of Respirology and Indonesian National Guidelines of Tuberculosis Control which
were adapted from the World Health Organization (WHO) recommendation: Treatment of
Tuberculosis: Guidelines for National Programmes (the algorithm is depicted in S1 Fig).[19–
21] Briefly, the diagnosis of active pulmonary TB was based on a clinical examination with the
support of microbiological and radiological findings. The review of the chest X-rays and com-
puted tomography (CT) scans was performed by two independent pulmonologists specialized
in TB (one from Indonesia (GS) and one from the Netherlands (MB)). The results were classi-
fied as being compatible with 1) active TB, 2) prior TB or 3) abnormalities other than TB. The
study was approved by the Faculty of Medicine University of Indonesia (FMUI) medical ethics
committee, and written informed consent was obtained.
Whole blood collection
Blood was collected in PAXgene tubes (PreAnalytix, Hombrechtikon, Switzerland) according
to the manufacturer’s protocol. The collection was performed at the patient’s first visit to our
clinic along with a routine blood draw for the standard uveitis work-up. The collected blood
was stored at -80˚C for further processing.
Real-time quantitative PCR
Total RNA was extracted from the whole blood samples using the Blood RNA Extraction Kit
(PreAnalytix) and subsequently reverse-transcribed into complementary DNA (cDNA)
according to the manufacturer’s instructions. The expression levels of 35 type 1 IFN-inducible
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genes selected based on previous reports[13–15, 22, 23] (CCL2, CCL7, CX3CR1, CXCL10,
DDX58, FCGR1B, GBP1, GBP4, IFI16, IFI27, IFI44, IFI44L, IFIH1, IFIT1, IFIT2, IFIT3,
IFITM1, IFNA1, IFNB1, IL15RA, IL1B, IRF7, ISG15, LY6E, MyD88, MxA, OAS1, OAS2,
RSAD2, SERPING1, STAT1, TBK1, TLR8, UBE2L6, and USP18) were determined. To calcu-
late the relative expression levels, all the samples were normalized to the expression of the
housekeeping gene ABL (ΔCt).[24]
Statistical analysis
Descriptive statistics (mean and standard deviation (SD) or median and interquartile range
(IQR)) were used to summarize demographic factors, age, gender, and the TB-related test
results (QFT, sputum smear, and TST). Then, the groups were compared using the non-
parametric Kruskal-Wallis test or chi-square test. Post hoc analysis was performed with the
Bonferroni test.
To identify which of the 35 type 1 IFN-inducible genes differed significantly between the
patients with active pulmonary TB without uveitis and the healthy controls, the Mann-Whit-
ney U test was performed. Due to significant age and gender differences between the groups,
the analysis was adjusted for age and gender using binary logistic regression.
All statistical analyses were performed in SPSS, and a P value <0.05 indicated statistical sig-
nificance. Unsupervised hierarchical clustering analysis of the identified genes was performed
using OmniViz version 6.1.1.13.0 (Instem scientific, Inc.)
Type 1 IFN signature score. Individual type 1 IFN-inducible genes were assigned a score
(ΔΔCt value) by deducting the ΔCt value of each gene in each subject from the average ΔCt
Table 1. General characteristic of the patients.
Total (n = 103) Active Pulmonary TB Without uveitis Uveitis with clinically diagnosed active pulmonary TB QFT (+) uveitis of unknown cause Healthy controls P value
(n = 10) (n = 12) (n = 58) (n = 23)
Gender, No.(%) 0.008
Male 38 (37) 7 (70) 8 (67) 16 (28) 7 (30)
Female 65 (63) 3 (30) 4 (33) 42 (72) 16 (70)
Age, mean
(SD), years
40 (15) 41 (16) 42 (17) 46 (13) 31 (9) 0.000
Microbiologic
evidence of Mtb
infection, No.
(%)
12 (12) 10 (100) 2 (17) 0 (0) 0 (0) 0.058
QFT-G valuea,
median (IQR),
IU/ml
2.8 (0.02–3.7) 2.2 (0.2–5.5) 1.4 (1.0–4.2) 5.0 (2.1–10.4) 0.01 (0.00–0.07) 0.000
QFT-G
positivea, No.
(%)
75 (72) 7 (70) 10 (83) 58 (100) 0 (0) 0.000
QFT-G
negativea, No.
(%)
28 (27) 3 (30) 1 (8) 0 (0) 23 (100)
TST > 10 mmb,
No.(%)
49 (83) NA 10 (100) 39 (84) NA 0.293
ATT at the time
of blood
samping
2 (2) 0 (0) 2 (17) 0 (0) NA NA
Abbreviations: SD, Standard Deviation; Mtb, Mycobacterium tuberculosis; IQR, Interquartile Range; QFT, QuantiFERON Gold test; TB, Tuberculosis; TST, Tuberculin
Skin Test; NA, Not Applicable.
a QFT-G indeterminate in 1/103 (1%) in suspected tuberculous uveitis with sputum AFB positive
b TST was done in 59 patients due to a temporary unavailability of tuberculin; 10 out of 12 uveitis patients with clinically diagnosed active pulmonary TB and 49 out of
58 QFT (+) unknown cause uveitis patients (in total 59 subjects). TST was not done in all active pulmonary TB patients and healthy controls.
https://doi.org/10.1371/journal.pone.0206073.t001
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value of that particular gene within the healthy control group and dividing by the standard
deviation (SD) of the ΔCt value of that particular gene in the healthy control group. Subse-
quently, a type 1 IFN signature score was assigned to the total gene set by calculating the sum
of the individual gene scores (ΔΔCt values).[23–25]
Receiver operating characteristic (ROC) curve analysis was used to identify the optimal cut-
off value of the type 1 IFN signature score associated with active TB. The maximum Youden
index (sensitivity + specificity − 1) was used to obtain the optimal cut-off point to discriminate
between the active pulmonary TB patients and the healthy controls.
Results
Patient groups
The characteristics of the patients and controls are summarized in Tables 1 and 2. A significant
difference was found in age and gender between the study groups. The post hoc analysis
revealed that the healthy controls were significantly younger than the QFT-positive group with
uveitis of unknown origin (p<0.0001). The post hoc analysis of the gender distributions did
not reveal any significant differences between the groups.
Among the 12 uveitis patients clinically diagnosed with active pulmonary TB, only 2 had
positive Mtb staining and PCR (GeneXpert) results in their sputum samples. QFT testing was
positive in 10/12 (83%) of these patients. Of the 10 patients with active pulmonary TB but
without uveitis, 7/10 (70%) were QFT-positive. Ocular characteristics of patients with uveitis is
presented in Table 2.
Type 1 IFN-inducible gene expression
Among the 35 type 1 IFN-inducible genes, 18 genes differed significantly in their expression
levels between the patients with active pulmonary TB without uveitis and the healthy control
Table 2. Ocular characteristics of patients with uveitis�.
Clinical
Characteristic
Uveitis with clinically diagnosed active pulmonary TB
N(%)
QFT (+) uveitis of unknown cause
N(%)
(Total n = 12) (Total n = 58)
Uveitis location
Anterior 1(8) 18(31)
Intermediate 0(0) 3(5)
Posterior 5(42) 11(19)
Panuveitis 6(50) 24(41.5)
Epi/scleritis 0(0) 2(3.5)
Laterality
Unilateral 8(67) 33(57)
Bilateral 4(33) 25(43)
Duration of
uveitis > 1 year
2 (17) 18(31)
Visual acuity by
Snellen chart
(median; IQR)
0.047; 0.005–0.13 0.045;0.008–2
� All patients had active uveitis though a majority consulted the ophthalmologist already in the late stage of the
disease
Abbreviations: TB, Tuberculosis; QFT, QuantiFERON Gold test; IQR, Interquartile Range.
https://doi.org/10.1371/journal.pone.0206073.t002
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group (S2 Fig). After adjustment for age and gender, the expression of 10 genes remained sig-
nificantly different between these two groups. These 10 genes (UBE2L6 (p = 0.004), FCGR1B
(p = 0.012), GBP1 (p = 0.013), IL1B (p = 0.015), MYD88 (p = 0.018), TLR8 (p = 0.02), IRF7
(p = 0.028), STAT1 (p = 0.032), SERPING1 (p = 0.036), and IFIT2 (p = 0.037)) were included
in the subsequent analyses.
Cluster analysis of the patient groups and the healthy controls
Unsupervised hierarchical clustering of the 10 active pulmonary TB patients without uveitis
and 23 healthy controls based on the 10 genes yielded two main clusters. Cluster 1 contained
the majority of the healthy controls (19/23; 83%); in contrast, cluster 2 contained the majority
of the active pulmonary TB patients without uveitis (9/10; 90%) (S3 Fig). Subsequently, the
two Mtb sputum-positive uveitis patients with clinically active pulmonary TB were included in
this analysis, and both patients were grouped in the cluster that contained 9/10 of the active
pulmonary TB patients without uveitis (cluster 2, Fig 1).
Due to the ability of this 10-gene expression pattern to distinguish the majority of the Mtb
sputum stain-positive active pulmonary TB patients (both with and without uveitis) from the
healthy controls, the same analysis was performed after including the 10 uveitis cases with clin-
ically diagnosed active pulmonary TB who were Mtb sputum stain negative. This analysis clus-
tered 7/10 cases (70%) with the majority of the healthy controls (cluster 1), whereas 3 cases
(30%) were clustered with the active pulmonary TB cases without uveitis (cluster 2; Fig 2).
Next, the analysis was performed for the 58 QFT-positive patients with uveitis of unknown
cause. This analysis revealed that 34/58 patients (59%) were clustered in the vicinity of the
majority of the active pulmonary TB patients without uveitis (clusters 2 and 1B, Fig 3), whereas
23/58 (37%) were clustered close to the majority of the healthy controls (cluster 1A, Fig 3).
Additionally, 1/58 patients (4%) was grouped together with 7 healthy controls and 1 active TB
without uveitis case (cluster 1C, Fig 3). However, the gene expression pattern in cluster 1B was
more similar to that of cluster 2, which contained the majority of the active pulmonary TB
cases.
Type 1 IFN gene signature score
Based on the 10-gene expression pattern, a type 1 IFN signature score was calculated for each
individual included in the study groups. This calculation revealed a significant difference
between the active pulmonary TB patients without uveitis and the healthy controls (p<0.0001;
Fig 4). The type 1 IFN signature score of QFT-positive patients with uveitis of unknown cause
had significantly lower scores than the active pulmonary TB patients without uveitis (P value
0.002) but significantly higher scores than the healthy controls (P value 0.01; Fig 4). In the
patients with uveitis and clinically diagnosed active pulmonary TB, the two sputum-smear-
positive TB uveitis patients and three other cases revealed type 1 IFN signature scores that
were comparable to those seen in the active pulmonary TB without uveitis group. Further-
more, in the QFT-positive patients with uveitis of unknown cause, the type 1 IFN signature
scores varied, with a range from scores comparable to those seen in the active pulmonary TB
(without uveitis) group to scores overlapping those seen in the healthy control group (Fig 4).
Further, we determined a type 1 IFN signature score cut-off value using ROC curve analysis
that yielded an area under the curve (AUC) of 0.961 with a P value <0.00001 (S4A Fig); a cut-
off value�5.61 displayed the highest sensitivity (100%), specificity (91%) and Youden index
(0.913) for the identification of active TB (S4B Fig and Fig 5A).
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Discussion
In this study, we demonstrate that a blood transcriptional signature of 10 type 1 IFN-inducible
genes differentiates QFT-positive uveitis patients into distinct different groups.
Type 1 IFN (IFNα/β)-inducible gene expression signatures in peripheral blood cells have
consistently been reported as a potential biomarker for active pulmonary TB compared with
signatures in healthy controls or patients with other diseases.[13] Berry et al. first reported the
association between active pulmonary TB and the expression of numerous type 1 IFN-induc-
ible genes in peripheral blood cells in regions with both an intermediate TB burden (London,
UK) and a high TB burden (South Africa)[13]. Importantly, these type 1 IFN-inducible gene
transcripts differed from those observed in systemic autoimmune diseases, including systemic
lupus erythematosus (SLE), which is among a group of systemic autoimmune diseases that
contains subgroups of patients displaying a type 1 IFN-inducible gene expression pattern.[13,
22, 26, 27] Several other studies have corroborated the use of type 1 IFN-inducible gene expres-
sion in the peripheral blood to distinguish active from latent TB infection.[14–16, 28, 29]
Moreover, a rapid normalization of the type 1 IFN gene expression pattern upon successful
ATT was reported.[13, 15] Together, these observations underscore the role of type 1 IFN sig-
naling in the pathogenesis of TB and the potential usefulness of the peripheral blood type 1
IFN transcriptome as a biomarker and monitoring tool in TB diagnostics and management.
However, no studies of type 1 IFN-inducible blood transcriptome have been conducted in uve-
itis cases in relation to TB infection.
Fig 1. Cluster analysis of patients with uveitis with clinically active, Mtb sputum positive, pulmonary TB and patients with active pulmonary TB without
uveitis. Unsupervised hierarchical clustering analysis based on 10 type 1 IFN-inducible genes (indicated on the right). Active pulmonary TB subjects indicate the
active pulmonary TB patients without uveitis. Uveitis TB subjects indicate uveitis patients with clinically diagnosed active pulmonary TB. Cluster 1 contains the
majority of the healthy controls (19/23; 83%) and one active pulmonary TB case without uveitis (1/10; 10%). Cluster 2 contains the majority of the active pulmonary
TB cases (9/10; 90%), two uveitis with clinically diagnosed active pulmonary TB with sputum-positive Mtb (2/2; 100%) and 4 healthy controls (4/23; 17%). Red
indicates increased gene expression levels compared to the geometric mean, and blue indicates decreased gene expression levels compared to the geometric mean.
Color intensity correlates with the magnitude of the calculated fold change.
https://doi.org/10.1371/journal.pone.0206073.g001
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In our study, we identified a peripheral blood cell transcriptome consisting of 10 type 1
IFN-inducible genes that were strongly associated with active pulmonary TB without uveitis.
When a type 1 IFN signature score was applied to this 10-gene set, a score�5.61 displayed the
optimal sensitivity and specificity for distinguishing active pulmonary (Mtb sputum smear-
positive) TB patients without uveitis from healthy controls. In line with this result, the two TB
uveitis cases diagnosed with active pulmonary TB and having positive Mtb sputum smear dis-
played a type 1 IFN signature score>5.61. This finding indicates that microbiologically proven
active pulmonary TB with or without uveitis is associated with high expression of type 1 IFN-
inducible genes. However, several additional uveitis cases, who were QFT-positive, displayed a
positive type 1 IFN signature despite being Mtb sputum negative.
Over-diagnosis of uveitis TB due to the lack of a gold standard diagnostic test (i.e., labora-
tory and radiological investigations) is a recognized problem that may result in overzealous
treatment of uveitis with ATT.[30] Within the uveitis group diagnosed with pulmonary TB on
clinical grounds solely, we found 7 cases with a type 1 IFN signature score<5.61. In these
cases, the uveitis was probably not related to active TB. Importantly, the type 1 IFN signature
scores revealed two subgroups within the QFT-positive patients with uveitis of unknown
cause. We propose that QFT-positive patients with uveitis of unknown cause and a type 1 IFN
signature score<5.61 are unlikely to have uveitis related to active TB infection. This conclu-
sion is supported by the high concordance within the set of 10 type 1 IFN-inducible genes
identified in our study and the type-1 IFN inducible genes identified in other studies that did
Fig 2. Cluster analysis of patients with uveitis who were sputum Mtb negative but were diagnosed with active TB infection on clinical grounds, patients with active
pulmonary TB without uveitis and healthy controls. Unsupervised hierarchical clustering analysis based on 10 type 1 IFN-inducible genes (indicated on the right).
Active pulmonary TB subjects indicate the active pulmonary TB patients without uveitis. Uveitis TB subjects indicate uveitis patients with clinically diagnosed active
pulmonary TB. Cluster 1 contains the majority of the healthy controls (19/23; 83%) and one active pulmonary TB case without uveitis (1/10; 10%). Cluster 2 contains the
majority of the active pulmonary TB cases (9/10; 90%) and 4 healthy controls (4/23; 17%). Ten uveitis patients had clinically diagnosed active pulmonary TB infections
but negative Mtb sputum tests. Only 3 patients (3/10; 30%) were grouped in cluster 2, which primarily contained clustered active pulmonary TB patients. Red indicates
increased gene expression levels compared to the geometric mean, and blue indicates decreased gene expression levels compared to the geometric mean. Color intensity
correlates with the magnitude of the calculated fold change.
https://doi.org/10.1371/journal.pone.0206073.g002
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compare active with latent TB.[16] Furthermore, this finding is in agreement with other stud-
ies that compared patients with active and latent TB and reported a rapid decline in peripheral
blood cell expression of type 1 IFN-inducible genes in active TB patients treated with a full
ATT regimen.[13, 15] Consequently, we expect that patients within the QFT-positive group
with uveitis of unknown cause who display a positive type 1 IFN signature score (�5.61) will
have a higher likelihood of having uveitis due to active TB infection and beneficial reaction to
ATT. Our series, however, lacks the results of type 1 IFN signature in QFT-positive patients
without uveitis. Nevertheless, we propose that measurement of a peripheral blood type 1 IFN
gene signature score can aid to the diagnostic workup and choice of treatment in patients with
QFT-positive uveitis, as is indicated in Fig 5B.
Elevated expression of type 1 IFN-inducible genes in peripheral blood cells is not specific to
active TB disease. Type 1 IFN gene signatures are also associated with systemic autoimmune
diseases, such as in Sjo¨gren’s syndrome cases (~55%), systemic lupus erythematosus (~50%),
and systemic sclerosis (~30%), and are also present in healthy control subjects (~5%).[22, 26,
27] However, differential expression of type 1 IFN-inducible genes between TB and systemic
autoimmune diseases is clear. MxA is a type 1 IFN-inducible gene that encodes an important
mediator of the early innate immune defense against viruses.[23] Elevated MxA expression is
part of the peripheral blood type 1 IFN signature in systemic autoimmune disease patients.[23]
Yet in our study elevated MxA gene expression was not found in peripheral blood from
patients with active pulmonary TB compared to healthy control subjects (S2 Fig). Therefore,
our data support differential involvement of type 1 IFN-inducible genes among different dis-
eases associated with type 1 IFN activity.[13]
Fig 3. Cluster analysis of QFT-positive patients with uveitis of unknown cause, patients with active pulmonary TB without uveitis and healthy controls.
Unsupervised hierarchical clustering analysis based on 10 type 1 IFN-inducible genes (indicated on the right). Active pulmonary TB subjects indicate the active
pulmonary TB patients without uveitis. Uveitis TB subjects indicate uveitis patients with clinically diagnosed active pulmonary TB Cluster 1 (A+B+C) contains the
majority of the healthy controls (19/23; 83%), cluster 1A contains 11 healthy controls (11/23; 48%) and 23 patients with uveitis of unknown cause were QFT
positive (23/58; 40%), cluster 1B contains 1 healthy control (1/23; 4%), 2 patients with active pulmonary TB without uveitis (2/20; 20%) and 16 patients with uveitis
of unknown cause were QFT positive (16/58; 28%) and cluster 1C contains 7 healthy controls (7/23; 30%), 1 patient with active pulmonary TB without uveitis (1/
10; 10%) and 1patient with uveitis of unknown cause were QFT positive (1/58; 2%). Cluster 2 contains the majority of the active pulmonary TB cases without
uveitis (9/10; 90%), 4 healthy controls (4/23; 17%) and 18 patients with uveitis of unknown cause were QFT positive (18/58; 31%). Red indicates increased gene
expression levels when compared to the geometric mean, and blue indicates decreased gene expression levels when compared to the geometric mean. Color
intensity correlates with the magnitude of the calculated fold change.
https://doi.org/10.1371/journal.pone.0206073.g003
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In autoimmune disease activated plasmacytoid dendritic cells (pDCs) are thought to be the
most dominant producers of type 1 IFN and thus inducers of the type 1 IFN gene signature,
although other type 1 IFN producing cells are not excluded.[31, 32] There is data supporting
involvement of pDCs in TB pathophysiology and pDCs may be a source of type 1 IFN in TB.
[33–38] Yet, the relation between pDCs, type1 IFN and TB pathophysiology remains hardly
studied so far and needs to be further elucidated. Moreover, other celtypes, including
Fig 4. Scatter plot of type 1 IFN signature scores for the four study groups. A type 1 IFN gene signature score was
calculated for every individual patient sample based on the expression of the 10-gene set. Each point represents one
individual. Horizontal bars indicate the median value within a group. Enlarged triangles within the TB uveitis group
represent the two individuals within that group with a sputum stain positive for Mtb. Statistical significance was
assessed using the Kruskal-Wallis test, and subgroup analyses were performed with Dunn’s multiple comparison test.
https://doi.org/10.1371/journal.pone.0206073.g004
Type I IFN gene signature: A tool to stratify high vs low-risk TB uveitis?
PLOS ONE | https://doi.org/10.1371/journal.pone.0206073 October 18, 2018 10 / 15
macrophages and epithelial cells may represent a source of type 1 IFN in TB.[39] And more
recently we demonstrated that Mtb infected retinal pigment epithelial cells are also strong pro-
ducers of type 1 IFN and as such may be relevant to TB-associated uveitis.[40]
Our study was of exploratory nature and set up to identify whether a peripheral type 1 IFN
gene signature could stratify Mtb-associated uveitis patients, either amongst patients with
active TB disease or healthy controls. This is especially relevant for the diagnostic problematic
group of patients that are QFT-positive and have uveitis of unknown cause, and subgroups
(positive and negative type 1 IFN signature) could indeed be recognized, and as such might be
qualified as high or low risk of having uveitis in relation to active TB. We did not include
QFT-negative uveitis patients in our study as they are never suspected of TB-associated uveitis.
However, it can be anticipated that a proportion of QFT-negative uveitis cases will be associ-
ated with a positive type-1 IFN gene signature, for instance in case of uveitis in association
with autoimmune disease or toxoplasmosis.
In conclusion, we identified a blood transcriptional signature of 10 type 1 IFN-inducible genes
highly expressed in active pulmonary TB patients. Although further validation studies are
required, our data suggest that this peripheral blood type 1 IFN gene signature has the potential to
stratify patients with suspected active TB infection-associated uveitis into groups with either a low
or high risk of having uveitis due to TB. We expect that this stratification forms a constructive
basis for future diagnostic and treatment studies in QFT-positive patients with uveitis.
Fig 5. Proposed algorithm for the diagnostic work-up of QFT-positive uveitis. A. Scatter plot of type 1 IFN signature scores for QFT-positive patients with uveitis of
unknown cause, patients with active pulmonary TB without uveitis and healthy controls. Each point represents one individual. Horizontal bars indicate the median value
within a group. Yellow horizontal bar marks the cut off value of 5.61 for a positive versus a negative type 1 IFN gene signature score. Therefore, symbols indicated in red
represent type1 IFN gene signature score positive individuals and blue symbols indicate type1 IFN gene signature score negative individuals. B. Algorithm for the
management of QFT-positive uveitis patients. QFT-positive patients with uveitis of known causes should be treated appropriately for that cause. In QFT-positive patients
with uveitis of unknown causes, the 10-gene type 1 IFN score can be calculated. When the score is 5.61 or more, we recommend to give the patient a full ATT regimen
and the necessary anti-inflammatory treatment regimen. When the score is less than 5.61, the patient can defer ATT and can undergo anti-inflammatory treatment with
or without an Isoniazid (INH) prophylaxis regimen with strict observation.
https://doi.org/10.1371/journal.pone.0206073.g005
Type I IFN gene signature: A tool to stratify high vs low-risk TB uveitis?
PLOS ONE | https://doi.org/10.1371/journal.pone.0206073 October 18, 2018 11 / 15
Supporting information
S1 Fig. Indonesian Society of Respirology (ISR) TB diagnostic guideline. Scheme depicting
the TB diagnostic algorithm in Indonesia. The guideline starts with evaluation of clinical signs
suggestive for tuberculosis (TB). In patients with signs suggestive of pulmonary TB infection,
an acid-fast staining examination from the sputum is required and a positive result leads to
diagnosis of active pulmonary TB. If the culture examinations from the sputum are negative,
radiologic imaging is reviewed and classified. When imaging is considered to exhibit signs of
active pulmonary TB, the patient is diagnosed with active pulmonary TB. Therefore, active
pulmonary TB will be either acid-fast bacillus (AFB) positive or AFB negative. The diagnosis
of AFB-positive active pulmonary TB is based on positive culture or positive GeneXpert out-
comes, and AFB-negative TB is based on radiologic signs of active pulmonary TB and clinical
improvement after anti-tuberculosis antibiotic treatment.
TB: tuberculosis, AFB: acid-fast bacillus, GeneXpert: a molecular test that detects bacterial
DNA from Mycobacterium tuberculosis, PCR: polymerase chain reaction, CXR: chest X-ray,
TST: tuberculin skin test.
(TIF)
S2 Fig. Type 1 IFN-inducible genes with significant differences in expression between active
pulmonary TB patients without uveitis and healthy controls. Of a total of 35 type 1 IFN-induc-
ible genes measured in the peripheral blood, 18 genes differed significantly in their expression
between the active pulmonary TB without uveitis patients and the healthy controls without correc-
tion for age differences between the groups. Statistical significance was assessed using the Mann-
Whitney U test. ���� P value<0.0001, ��� P value<0.001, �� P value<0.01, � P value<0.05.
(TIF)
S3 Fig. Cluster analysis of active pulmonary TB patients without uveitis and healthy con-
trols based on type 1 IFN-inducible gene expression patterns. Unsupervised hierarchical
clustering analysis based on 10 type 1 IFN-inducible genes (indicated on the right). Active pul-
monary TB subjects indicate the active pulmonary TB patients without uveitis. Cluster 1 con-
tains the majority of the healthy controls (19/23; 83%) and one active pulmonary TB case
without uveitis (1/10; 10%). Cluster 2 contains the majority of the active pulmonary TB cases
without uveitis (9/10; 90%) and 4 healthy controls (4/23; 17%). Red indicates increased gene
expression levels when compared to the geometric mean, and blue indicates decreased gene
expression levels when compared to the geometric mean. Color intensity correlates with the
magnitude of the calculated fold change.
(TIF)
S4 Fig. ROC curve analysis and Youden Index calculation for determining the optimal cut-
off value of type 1 IFN signature score. A. The ROC curve analysis and area under the curve
(AUC) B. Youden index analyses indicate that a type 1 IFN signature score cut-off value�5.61
represents the optimal cut-off value for distinguishing active pulmonary TB patients without
uveitis from healthy controls with 100% sensitivity, 91% specificity and a Youden index of
0.913.
(TIF)
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